Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to enable proton-transporting ATPase activity, rotational mechanism. Acts upstream of or within several processes, including apical protein localization; embryonic retina morphogenesis in camera-type eye; and notochord cell vacuolation. Predicted to be located in clathrin-coated vesicle membrane; synaptic vesicle membrane; and vacuolar membrane. Predicted to be part of proton-transporting V-type ATPase, V0 domain. Predicted to be active in membrane. Is expressed in several structures, including digestive system; gonad; integument; nervous system; and unfertilized egg. Human ortholog(s) of this gene implicated in early-onset epilepsy 3 and thyroid gland carcinoma. Orthologous to human ATP6V0C (ATPase H+ transporting V0 subunit c). [provided by Alliance of Genome Resources, Feb 2025]